Asahi Kasei's $920 million takeover of German biotech Aicuris in April has paid off with FDA approval for the herpes simplex ...
New data show favorable outcomes with subcutaneous infliximab following intravenous infliximab interruption, regardless of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results